Clinical Trials Logo

Plaque Psoriasis clinical trials

View clinical trials related to Plaque Psoriasis.

Filter by:

NCT ID: NCT01722331 Completed - Plaque Psoriasis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

reSURFACE 1
Start date: December 6, 2012
Phase: Phase 3
Study type: Interventional

This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.

NCT ID: NCT01710046 Completed - Plaque Psoriasis Clinical Trials

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Start date: March 2013
Phase: Phase 2
Study type: Interventional

There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.

NCT ID: NCT01707368 Completed - Plaque Psoriasis Clinical Trials

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Start date: October 2012
Phase:
Study type: Observational

The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient`s individual application habits under daily use conditions.

NCT ID: NCT01707043 Completed - Plaque Psoriasis Clinical Trials

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

PSTaclonex
Start date: October 2012
Phase: Phase 4
Study type: Interventional

This is an open label, investigator-blinded, cross over, prospective, single center study of subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension will each be applied topically once daily. The primary objective is to assess the patient preference for Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment compared to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension in the treatment of plaque psoriasis.

NCT ID: NCT01700985 Completed - Psoriasis Clinical Trials

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Start date: May 2012
Phase: Phase 2
Study type: Interventional

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

NCT ID: NCT01698333 Completed - Plaque Psoriasis Clinical Trials

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Start date: April 2012
Phase: Phase 2
Study type: Interventional

Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.

NCT ID: NCT01680159 Completed - Psoriatic Arthritis Clinical Trials

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment with Remicade® at 5 mg/kg every 8 weeks but decreased thereafter.

NCT ID: NCT01677598 Completed - Plaque Psoriasis Clinical Trials

A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries

MARCOPOLO
Start date: December 2011
Phase: Phase 4
Study type: Observational

The purpose of this study is to determine how patients use ustekinumab (label-recommended or other/missed dose interval) in Asia-Pacific countries.

NCT ID: NCT01646073 Completed - Plaque Psoriasis Clinical Trials

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

Start date: August 2012
Phase: Phase 3
Study type: Interventional

A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.

NCT ID: NCT01634087 Completed - Plaque Psoriasis Clinical Trials

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

Start date: June 2012
Phase: Phase 2
Study type: Interventional

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.